Biassoni R, Vaccari A
Br J Pharmacol. 1985 Jun;85(2):447-56. doi: 10.1111/j.1476-5381.1985.tb08881.x.
The action of the antithyroid drugs methimazole (MMI) and propylthiouracil (PTU) on the binding of [3H]-imipramine, [3H]-5-hydroxytryptamine [3H]-5-HT) (to 5-HT1-receptors) and [3H]-spiperone (to 5-HT2-, D2-receptors) of rat brain membranes has been examined. The synaptosomal uptake of [3H]-5-HT was also studied. Micromolar concentrations of the disulphide bond reducing agents MMI, PTU, dithiothreitol (DTT) and mercaptoethanol increased both the binding of [3H]-imipramine and the uptake of [3H]-5-HT. In contrast, they decreased the number of 5-HT1-receptors, and did not affect 5-HT2-and D2-sites. Reaction with membrane-bound sulphydryl (SH) groups by micromolar concentrations of N-ethylmaleimide (NEM), hydroxymercuribenzoic acid (PCMB), or Ellman's reagent (DTNB) decreased the binding of [3H]-imipramine, the number of 5-HT1-receptors, and the uptake of [3H]-5-HT. Millimolar concentrations of NEM were necessary in order to decrease partially 5-HT2- and D2-receptors. The effects of NEM on imipramine recognition sites and on the uptake of 5-HT could be prevented by DTT; protection was not obtained in other receptor systems. Three groups of receptors have been, thus, postulated, based upon their different sensitivity towards alterations in membrane [disulphide bridges in equilibrium SH] equilibrium: Group I, including imipramine recognition sites and the uptake system for 5-HT; Group II, including 5-HT1-receptors; Group III, including 5-HT2-and D2-receptors.
研究了抗甲状腺药物甲巯咪唑(MMI)和丙硫氧嘧啶(PTU)对大鼠脑膜中[3H]-丙咪嗪、[3H]-5-羟色胺([3H]-5-HT,作用于5-HT1受体)以及[3H]-螺哌隆(作用于5-HT2、D2受体)结合的影响。还研究了[3H]-5-HT在突触体中的摄取情况。微摩尔浓度的二硫键还原剂MMI、PTU、二硫苏糖醇(DTT)和巯基乙醇增加了[3H]-丙咪嗪的结合以及[3H]-5-HT的摄取。相反,它们减少了5-HT1受体的数量,且不影响5-HT2和D2位点。微摩尔浓度的N-乙基马来酰亚胺(NEM)、对氯汞苯甲酸(PCMB)或埃尔曼试剂(DTNB)与膜结合的巯基(SH)基团反应,降低了[3H]-丙咪嗪的结合、5-HT1受体的数量以及[3H]-5-HT的摄取。为了部分降低5-HT2和D2受体,需要毫摩尔浓度的NEM。NEM对丙咪嗪识别位点和5-HT摄取的影响可被DTT阻止;在其他受体系统中未获得保护作用。因此,根据它们对膜[处于平衡状态的SH中的二硫键]平衡变化的不同敏感性,推测出三组受体:第一组,包括丙咪嗪识别位点和5-HT摄取系统;第二组,包括5-HT1受体;第三组,包括5-HT2和D2受体。